Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 601–700 of 892
Postnatal therapeutic approaches in genetic neurodevelopmental disorders
Levy, G., & Barak, B. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.293133 · Cited by 10
“, 2019), with promising results that have led to clinical success (Mingozzi and High, 2011; Ylä-Herttuala, 2012).”
BackgroundJanelidze, S., Nordström, U., Kügler, S., & Brundin, P. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2779 · Cited by 12
“During the past two decades, adeno-associated virus (AAV) vectormediated gene delivery has emerged as a potential therapeutic strategy in several diseases, including PD [6,7].”
BackgroundOhgidani, M., Furugaki, K., Shinkai, K., Kunisawa, Y., Itaka, K., Kataoka, K., & Nakano, K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.006 · Cited by 11
10 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
Tourdot, S., Abdolzade‐Bavil, A., Bessa, J., Broët, P., Fogdell‐Hahn, A., Giorgi, M., Jawa, V., Kuranda, K., Legrand, N., Pattijn, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1725369 · Cited by 11
“Hence, deciphering the mechanisms pertaining to AAV immunogenicity is fundamental to designing immune tolerance induction regimens, which will allow successful expression of the transgene and re-dosing if necessary.(19) At the occasion of the EIP 10th Open Symposium on Immunogenicity of Biopharmaceuticals, 30 experts…”
BackgroundHareendran, S., Ramakrishna, B., & Jayandharan, G. R. (2016) · European Journal of Immunology · doi:10.1002/eji.201545867 · Cited by 10
Targeted gene delivery systems for T-cell engineering
Wang, F., Huang, Y., Li, J., Zhou, W., & Wang, W. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00954-6 · Cited by 13
Adeno-Associated Viral Vectors in the Treatment of Epilepsy
Mullagulova, A., Timechko, E. E., Solovyeva, V., Yakimov, A. M., Ibrahim, A., Dmitrenko, D., Sufianov, A., Sufianova, G., & Rizvanov, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212081 · Cited by 8
Chanani, P., Rezaei, N., Dormiani, K., Shokatian, M., & Ata-abadi, N. S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102682 · Cited by 13
Progress With Optogenetic Functional Mri and Its Translational Implications
Weitz, A. J., & Lee, J. H. (2013) · Future Neurology · doi:10.2217/fnl.13.42 · Cited by 10
Chitosan-based core–shell structured particles for in vivo sustainable gene transfection
Lin, F., Rong, J.-L., Wang, M., Bao, D., Wang, Y., Gong, Z.-X., Gu, Y., Zhao, Y., & Ge, X. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb02074c · Cited by 10
Korczeniewska, O. A., James, M. H., Eliav, T., Rider, G. K., Mehr, J. B., Affendi, H., Aston‐Jones, G., & Benoliel, R. (2021) · European Journal of Pain · doi:10.1002/ejp.1887 · Cited by 11
“Additionally, in vivo animal studies and clinical trials have shown efficient AAV- mediated transduction of several cell types, including neurons (Bainbridge et al., 2008; Mingozzi & High, 2011).”
BackgroundDiscovery of novel DNA viruses in small mammals from Kenya
Ochola, G. O., Li, B., Obanda, V., Ommeh, S. C., Ochieng, H., Yang, X., Onyuok, S. O., Shi, Z., Agwanda, B. R., & Hu, B. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.06.001 · Cited by 10
“Because of their long-lasting expression and non-apparent pathogenicity, AAVs have been frequently used as viral vectors in gene therapy researches (Mingozzi and High, 2011).”
BackgroundMethodComparative Next-Generation Sequencing of Adeno-Associated Virus Inverted Terminal Repeats
Petri, K., Fronza, R., Gabriel, R., Kaeppel, C., Nowrouzi, A., Linden, R. M., Henckaerts, E., & Schmidt, M. (2014) · BioTechniques · doi:10.2144/000114170 · Cited by 14
A chemical switch for controlling viral infectivity
Hörner, M., Kaufmann, B., Cotugno, G., Wiedtke, E., Büning, H., Grimm, D., & Weber, W. (2014) · Chemical Communications · doi:10.1039/c4cc03292f · Cited by 11
Shanks, J. A., Herring, N., Johnson, E., Liu, K., Li, D., & Paterson, D. J. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08507 · Cited by 14
“Adeno viruses (Ad) and AAV are powerful tools for altering gene expression because of their high transfection efficiency and low risk of pathogenicity.(12) They also have increased efficiency at infecting multiple cell types, including Abstract—Reduced cardiomyocyte excitation–contraction coupling and downregulation o…”
BackgroundApplying switchable Cas9 variants to in vivo gene editing for therapeutic applications
Mills, E. M., Barlow, V. L., Luk, L. Y. P., & Tsai, Y. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09488-2 · Cited by 10
Viral and Nonviral Transfer of Genetic Materials to Adipose Tissues: Toward a Gold Standard Approach
Romanelli, S. M., & MacDougald, O. A. (2020) · Diabetes · doi:10.2337/dbi20-0036 · Cited by 11
“with vector accumulation in reticuloendothelial organs (liver, lung, heart, and kidney) limits adipocyte transduction efficiency (1,2,5,6).”
BackgroundSharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub4 · Cited by 10
Ahn, J., Woo, H., Ko, A., Khim, M., Kim, C., Park, N. H., Song, H. Y., Kim, S. W., & Lee, H. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0998-1 · Cited by 10
“rAAV vectors have been approved by the Food and Drug administration for Phase I/II clinical trials in various types of human diseases [18].”
BackgroundWorgall, S., & Crystal, R. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00034-3 · Cited by 15
Mondo, E., Moser, R. P., Gao, G., Mueller, C., Sena‐Esteves, M., Sapp, E., Pfister, E. L., O'Connell, D. C., Takle, K. A., Erger, K. E., et al. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-180302 · Cited by 11
“Several AAV serotypes, most notably AAV2, have been used in clinical trials for gene therapy of inherited diseases [5].”
Adeno-Associated Viral Vector Manufacturing: Keeping Pace with Accelerating Clinical Development
Wright, J. F. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.2514 · Cited by 10
“…of safety and long-term efficacy for some diseases including an inherited retinal disorder and hemophilia B in human clinical studies (reviewed in Mingozzi and High, 2011), the probability of clinical success for many other AAV programs at the preclinical and early clinical stages appears to…”
Optimized in vivo base editing restores auditory function in a DFNA15 mouse model
Wang, M., Zhang, Z., Wang, X., Zhang, L., Chen, X., Li, N., Sun, Q., Lu, Y., He, Z., Yang, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63613-w · Cited by 12
“The authors demonstrated that, starting from 2 to 4 months of age, mutant mice exhibited a progressive increase in hearing thresholds measured by ABR compared to wild-type mice.”
Cell and scaffold surface engineering to enhance cell migration and tissue regeneration
Maerz, T., Mu, R. R., & Baker, K. C. (2013) · Surface Innovations · doi:10.1680/si.13.00023 · Cited by 9
Targeted Gene Silencing to Induce Permanent Sterility
Dissen, G. A., Lomniczi, A., Boudreau, R. L., Chen, Y., Davidson, B. L., & Ojeda, S. (2012) · Reproduction in Domestic Animals · doi:10.1111/j.1439-0531.2012.02080.x · Cited by 9
“The AAV vector is derived from a non-pathogenic virus, which has contributed to its acceptance for gene therapy studies in humans (Mingozzi and High, 2011).”
BackgroundWeger, S., Hammer, E., Gonsior, M., Stutika, C., & Heilbronn, R. (2016) · Journal of Virology · doi:10.1128/jvi.03120-15 · Cited by 10
“The AAV ITRs also represent the key element of recombinant AAV (rAAV) vectors, which have been developed into very effective tools for the long-term expression of therapeutic genes in the clinical treatment of monogenic diseases, such as congenital blindness and hemophilia (11, 12).”
BackgroundInductively actuated micro needles for on-demand intracellular delivery
Kavaldzhiev, M. N., Perez, J. E., Sougrat, R., Bergam, P., Ravasi, T., & Kosel, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-28194-3 · Cited by 10
A Mixed-Surface Polyamidoamine Dendrimer for In Vitro and In Vivo Delivery of Large Plasmids
Srinageshwar, B., Florendo, M. N., Clark, B., Johnson, K. A., Munro, N., Peruzzaro, S., Antcliff, A., Andrews, M., Figacz, A., Swanson, D. R., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070619 · Cited by 9
Zabaleta, N., Salas, D., Páramo, M. D. L. Á., Hommel, M., Ferreira, V., Hernández-Alcoceba, R., Prìeto, J., Bilbao, J. I., & González‐Aseguinolaza, G. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.183 · Cited by 10
Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α
Vásquez, M., Consuegra‐Fernández, M., Aranda, F., Jimenez, A., Tenesaca, S., Fernández-Sendin, M., Gomar, C., Ardaiz, N., Trani, C. A. D., Casares, N., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801462 · Cited by 9
Chan, C.-C., Lai, C., Wu, C.-J., Chen, L., Tao, M., & Kuo, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.161 · Cited by 9
“26 In a murine model of hemophilia B, hepatocyte-restricted factor IX expression sustained therapeutic protein levels and evaded unwanted immune responses.”
Kim, M., Oh, S., Kim, S., Kim, I., Kim, J., Han, J. H., Ahn, J. W., Chung, S., Jang, J., Shin, J. E., et al. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00349-y · Cited by 10
Therapeutic Gene Editing in Dyslipidemias
Zadeh, S. S. T., & Shapiro, M. D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508286 · Cited by 9
Rodriguez, A., Banazadeh, A., Ali, A. E., Singh, R., & Zhou, C. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.11.005 · Cited by 9
In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model
Gopalappa, R., Lee, M., Kim, G., Jung, E. S., Lee, H., Hwang, H.-Y., Lee, J. G., Kim, S. J., Yoo, H. J., Sung, Y. H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.027 · Cited by 8
Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies
Pipe, S. W., Poma, A., Rajasekhar, A., Everington, T., Sankoh, S., Allen, J., Cataldo, J., & Crombez, E. A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015184 · Cited by 9
Adeno-associated virus 2/9 delivery of Cre recombinase in mouse primary afferents
Abdallah, K., Nadeau, F., Bergeron, F., Blouin, S., Blais, V., Bradbury, K. M., Lavoie, C. L., Parent, J., & Gendron, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-25626-y · Cited by 11
Gene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 9
Electrophoresis-Mediated Characterization of Full and Empty Adeno-Associated Virus Capsids
Peña, A. C. D., Masto, L., Atwood, J., & Tripathi, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c01813 · Cited by 9
Therapeutic thoroughfares for adults living with Pompe disease
Schoser, B. G. H., & Laforêt, P. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001092 · Cited by 9
Strategies for More Rapid Translation of Cellular Therapies for Children: A US Perspective
López-Sánchez, R. C., Silberstein, L. E., Lindblad, R., Welniak, L. A., Mondoro, T. H., & Wagner, J. E. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3383 · Cited by 9
Larsen, C. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.05.005 · Cited by 8
Gene Delivery into Cells and Tissues
Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00035-5 · Cited by 10
Ohta, T., Hashida, Y., Higuchi, Y., Yamashita, F., & Hashida, M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.10.025 · Cited by 8
Sanchez–Daza, A., Li, C., Andrews, B. A., Asenjo, J. A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.043 · Cited by 9
Farraha, M., Barry, M. A., Lu, J., Pouliopoulos, J., Le, T. Y. L., Igoor, S., Rao, R., Kok, C., Chong, J. J. H., & Kizana, E. (2019) · Gene Therapy · doi:10.1038/s41434-019-0097-0 · Cited by 8
Cellular Reprogramming and Its Potential Application in Alzheimer’s Disease
Zhou, C., Ni, W., Zhu, T., Dong, S., Sun, P., & Hua, F. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.884667 · Cited by 8
“These approaches may enable the development of gene therapies for wide-ranging degenerative diseases, such as AD (Mingozzi and High, 2011).”
BackgroundIn vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification
Ebrahimi, P., Davoudi, E., Sadeghian, R., Zadeh, A. Z., Razmi, E., Heidari, R., Morowvat, M. H., & Sadeghian, I. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03141-4 · Cited by 8
“These challenges include issue with targeting and expressing specifically, gene silencing, the risk of insertional mutagenesis in host cells, and immune responses to the vector (Mingozzi and High 2011).”
Najera, S. S., Nicastri, A., Bing, S. J., Sajib, A. M., Ternette, N., & Mazor, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101506 · Cited by 9
“7,8 Recent evidence showed that CD8 + T cell response was elicited when immunizing mice with SaCas9 prior to the transduction of hepatocytes with AAV-CRISPR-Cas9 vector, resulting in hepatocyte apoptosis and failure of the genome editing procedure.”
McGuire, T. K., Stasiewicz, M., Woods, I., Dervan, A. G., & O’Brien, F. J. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300030 · Cited by 8
Huang, Z., Yang, T., Yu, J., Gao, Y., Weng, Y., Huang, Y., & Li, S. (2024) · Biomaterials Science · doi:10.1039/d3bm01981k · Cited by 7
Development of an adipose-tropic AAV capsid ablating liver tropism
Huang, W., Bates, R., Appana, B., Mohammed, T., & Cao, L. (2024) · iScience · doi:10.1016/j.isci.2024.110930 · Cited by 8
Scientific overview: 2013 BBC plenary symposium on tobacco addiction
Biasi, M. D., McLaughlin, I., Perez, E. E., Crooks, P. A., Dwoskin, L. P., Bardo, M. T., Pentel, P. R., & Hatsukami, D. K. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.05.013 · Cited by 7
“These vectors have shown no important toxicity in clinical trials for the transfer of other types of genes (Mingozzi and High, 2011).”
BackgroundSi, G., Elzes, M. R., Engbersen, J. F. J., & Paulusse, J. M. J. (2018) · Polymers · doi:10.3390/polym10060687 · Cited by 7
Cho, M., Jung, K., Kim, S., Kim, I., Kim, M., Shin, M., Lee, H., Park, K. I., & Jang, J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0057-8 · Cited by 7
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fāng, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 8
Optimizing the adeno-associated Viral Vector System: a Brief Summary
Hacker, U. T., & Büning, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.69 · Cited by 8
Osting, S., Bennett, A. D., Power, S., Wackett, J., Hurley, S. A., Alexander, A. L., Agbandje‐McKenna, M., & Bürger, C. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.4 · Cited by 7
Pu, L., Wang, J., Li, N., Chai, Q., Irache, J. M., Wang, G., Tang, J. Z., & Gu, Z. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b02592 · Cited by 7
Rincón, M. Y., Prada, C. E., López, M., Castillo, V., Echeverría, L. E., & Serrano, N. C. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5535 · Cited by 8
“…in the design of a gene therapy strategy: the therapeutic gene that will be cloned into the transgene expression cassette; the target cells or tissues in which the vector will deliver the genetic material; and the viral vector used to facilitate entry of the gene into the target tissue [7].”
Will Optogenetics Be Used To Treat Chronic Pain Patients?
Beaudry, H., Daou, I., Ribeiro‐da‐Silva, A., & Séguéla, P. (2017) · Pain Management · doi:10.2217/pmt-2016-0055 · Cited by 7
Combination Therapy Is the New Gene Therapy?
Ronzitti, G., & Mingozzi, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.008 · Cited by 8
“AAV vectors are effective and safe tools for in vivo liver transduction as demonstrated in both preclinical animal models and clinical trials.(3) Induction of robust transgene-specific tolerance by AAV-mediated liver gene transfer has been documented in several studies and is dependent on the induction of regulatory T…”
BackgroundSelf-citationLaforêt, P., Oldfors, A., Malfatti, E., Vissing, J., Colle, M.-A., Durán, J., Gentry, M. S., Guinovart, J. J., Hurley, T. D., Kakhlon, O., et al. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.01.010 · Cited by 7
Self-citationGenome editing technologies and their potential to treat neurologic disease
Madigan, N. N., Staff, N. P., Windebank, A. J., & Benarroch, E. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004558 · Cited by 7
“Similarly, there have been a number of clinical trials for AAV gene therapy in muscle, including limb-girdle muscular dystrophies, spinal muscle atrophy, and Becker and Duchenne muscular dystrophies (case 2).(23,54) The correction of dystrophin coding mutations in Duchenne or Becker muscular dystrophies has emerged as…”
BackgroundCartilage Repair and Regeneration
Zorzi, A. R., & de Miranda, J. B. (2018) · InTech eBooks · doi:10.5772/67903 · Cited by 8
Toward a gene therapy for neurological and somatic MPSIIIA
Haurigot, V., & Bosch, F. (2013) · Rare Diseases · doi:10.4161/rdis.27209 · Cited by 9
Chen, X., Sun, M., Ma, X., Ma, Y., & Chen, B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101390 · Cited by 7
Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives
Khawaja, S., Ali, R. H., Ahmed, I., & Umair, M. (2025) · Current Genomics · doi:10.2174/0113892029361490250310041259 · Cited by 11
“These therapies have demonstrated remarkable success, offering not only the potential to halt disease progression but, in some cases, to reverse damage [11, 12].”
Targeted deletions in human mitochondrial DNA engineered by Type V CRISPR–Cas12a system
Nikitchina, N., Heckel, A., Shebanov, N., Mazunin, I., Tarassov, I., & Entelis, N. (2025) · NAR Molecular Medicine · doi:10.1093/narmme/ugaf021 · Cited by 8
Huang, X., Wang, X., Li, L., Qizhao, W., Xu, W., Wu, W., Xie, X., & Diao, Y. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17858 · Cited by 6
Hoffman, J. A., Denton, N., Sims, J. J., Meggersee, R., Zhang, Z., Olagbegi, K., & Wilson, J. M. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.050 · Cited by 7
Zhang, Y., Wang, L., Wang, L., Yang, J. C., Wu, X., Xiao, X., & Wang, J. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.041 · Cited by 7
Characterization and biodistribution of under-employed gene therapy vector AAV7
Yost, S. A., Firlar, E., Glenn, J. D., Carroll, H. B., Foltz, S. J., Giles, A. R., Egley, J. M., Firnberg, E., Cho, S., Nguyen, T. T. H., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01163-23 · Cited by 8
“Although their safety profile and ability to deliver genetic cargo to cells are promising, further engineering opportunities exist in order to improve tissue specificity, immune detection avoidance, and ease of manufacturing (3).”
BackgroundLee, M. H., Kang, S., Um, K. H., Lee, S. W., Hwang, H., Baek, K., & Choi, J. W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04816-x · Cited by 7
“This poses an intricate challenge that demands resolution to minimize off-target effects instigated by the leakage of therapeutic transgenes into peripheral blood circulation [3, 17].”
BackgroundMethodNew developments in the treatment of pediatric hemophilia and bleeding disorders
Branchford, B. R., Monahan, P. E., & Paola, J. D. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835bf77e · Cited by 6
Yang, E., Li, X., & Jin, N. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0351-0 · Cited by 6
“A novel gene transfer strategy is developed for the effective delivery system and the clinical practice [40, 41].”
Evaluation of BMP-2 Minicircle DNA for Enhanced Bone Engineering and Regeneration
Zimmermann, A., Hercher, D., Regner, B., Frischer, A., Sperger, S., Redl, H. R., & Hacobian, A. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200427121350 · Cited by 7
Relationship between bio-effects and energy transduction during nanoparticle-mediated photoporation
Kumar, S., Chong, C., Voorhees, T. J., Thadhani, N. N., & Prausnitz, M. R. (2020) · Journal of Applied Physics · doi:10.1063/5.0021834 · Cited by 6
Parsza, C. N., Gómez, D. L. M., Simonin, J. A., Belaich, M. N., & Ghiringhelli, P. D. (2020) · Current Gene Therapy · doi:10.2174/1566523220999201217155945 · Cited by 6
Donaueschingenstrasse 13, 1. V., Brenner, T., Posa-Markaryan, K., Hercher, D., Sperger, S., Heimel, P., Keibl, C., Nürnberger, S., Grillari, J., Redl, H. R., et al. (2021) · European Cells and Materials · doi:10.22203/ecm.v041a18 · Cited by 7
“…production, further improvement of therapeutic vector bio-efficacy, such as the simultaneous knockdown of transgene inhibitors, is considered to support successful translation of non-viral vectors to the clinic (Al-Dosari and Gao, 2009; Kay, 2011; Mingozzi and High, 2011; Wang et al., 2013).”
BackgroundA Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno‐Associated Virus
Kelemen, R. E., Mukherjee, R., Cao, X., Erickson, S. B., Zheng, Y., & Chatterjee, A. (2016) · Angewandte Chemie · doi:10.1002/ange.201604067 · Cited by 8
Use of a Lower Dosage Liver-Detargeted AAV Vector to Prevent Hamster Muscular Dystrophy
Rotundo, I. L., Lancioni, A., Savarese, M., D’Orsi, L., Iacomino, M., Nigro, G., Piluso, G., Auricchio, A., & Nigro, V. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.121 · Cited by 6
“Recombinant adeno-associated viruses (AAVs) have been identified as one of the best options for gene delivery as they provide significantly longer transgene expression and do not exhibit pathogenicity in humans (Berns and Linden, 1995; Hasbrouck and High, 2008; Mingozzi and High, 2011).”
BackgroundWilliams, E. G. L., Hutt, O. E., Hinton, T. M., Larnaudie, S. C., Le, T., MacDonald, J. M., Gunatillake, P. A., Thang, S. H., & Duggan, P. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01168 · Cited by 6
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Self-citationLiskovykh, M. A., Larionov, V., & Kouprina, N. (2021) · Current Protocols · doi:10.1002/cpz1.236 · Cited by 6
Gene delivery into cells and tissues
Nelson, C. E., Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00030-7 · Cited by 9
Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans
Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G. (2023) · Biomedicines · doi:10.3390/biomedicines11020523 · Cited by 5
Post-polymerization functionalized sulfonium nanogels for gene delivery
Kusmus, D. N. M., van Veldhuisen, T. W., Michel‐Souzy, S., Cornelissen, J. J. L. M., & Paulusse, J. M. J. (2024) · RSC Applied Polymers · doi:10.1039/d4lp00011k · Cited by 5
New Insights Into Genetic Right Ventricular Cardiomyopathies
Garcia-Montero, M., Fanous, Y., Krahn, A. D., Davies, B., Cadrin‐Tourigny, J., & Roberts, J. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.02.020 · Cited by 9
Ossi, L., Marie, H., Schulte, M., & Sponchioni, M. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466219 · Cited by 6
Optimization of an adeno-associated viral vector for epidermal keratinocytes in vitro and in vivo
Shen, Q., Suga, S., Moriwaki, Y., Du, Z., Aizawa, E., Okazaki, M., Belmonte, J. C. I., Hirabayashi, Y., Suzuki, K., & Kurita, M. (2024) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2024.07.006 · Cited by 5
A p21 reporter iPSC line for evaluating CRISPR-Cas9 and vector-induced stress responses
Sun, Y.-D., Li, G., Zhang, F., Cheng, T., Zhang, J., & Zhang, X. (2024) · Stem Cells · doi:10.1093/stmcls/sxae056 · Cited by 6
“14 However, they have also been reported to induce p53-dependent apoptosis, 15-17 partially attributed to the cellular recognition of AAV inverted terminal repeats (ITRs) by classical DNA damage response (DDR) molecules (Figure 4A).”
Vector Decoys Trick the Immune Response
VandenDriessche, T., & Chuah, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006633 · Cited by 6
Stem cells and regenerative therapies for Parkinson’s disease
Barker, R. A., & Farrell (2012) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s16087 · Cited by 9
“With respect to the viral delivery of trophic agents, problems relate to the dose of agent delivered and its volume of distribution and the fact that once delivered, the agent cannot be retrieved.(83,84) As a result, regulatable systems are being developed along with the introduction of drug-activated suicide genes th…”
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Khan, A., Aljarbou, A. N., Khan, S., & Khan, M. A. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2038613 · Cited by 5
Weger, S., Hammer, E., & Heilbronn, R. (2014) · Journal of Virology · doi:10.1128/jvi.02350-14 · Cited by 6
“Gene delivery approaches with rAAV vectors have allowed major improvements in the treatment of monogenic diseases, such as congenital blindness and hemophilia (6, 7).”
BackgroundXiong, Y., Zhang, M., Zhou, J.-H., Li, Y., You, F., Wen, Y., He, W., & Chen, Q. (2018) · Intervirology · doi:10.1159/000493799 · Cited by 5
Applications of Virus Vector–Mediated Gene Therapy in China
Lin, Q., Deng-gao, W., Zhang, Z., & Liu, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.238 · Cited by 5
“27,28 Furthermore, inserting short peptides into AAV capsids by rational design and selecting satisfactory variants through directed evolution enable AAVs specifically to transduce more cell types or decrease neutralization by anti-AAV antibodies.”
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.